Q2 2022

Filed Aug 15, 2022 · 10-Q · 46 days after period end · 0001583771-22-000009

Q2 2022 · 10-Q

Revenue

$0.00

— vs Q2 2021

Net Income

-$19.91M

N/M vs Q2 2021

EPS Diluted

-$5.22

N/M vs Q2 2021

Operating Income-$19,998,121N/M

Operating Cash Flow

Same quarter

Metric	Q2 2022	Q2 2021	Q2 2020	Q2 2019
Revenue	$0.00	$0.00	$0.00	—
Net Income	-$19.91M	-$7.67M	-$4.94M	-$1.02M
EPS Diluted	-$5.22	-$0.10	-$0.58	-$7.48

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Hepion Pharmaceuticals, Inc. · CIK 1583771 · Engraved from SEC EDGAR